The revenue miss and continued cash burn are negative near-term catalysts. However, the maintained FY2026 guidance of >$40M revenue and the Robocath acquisition provide a longer-term narrative. Watch for sequential revenue growth in Q2 and Q3 as manufacturing ramps for GenesisX and MAGiC; any delay in hitting the 500-catheters/month target would be a further negative signal.
Price Chart
Executive Summary
Stereotaxis reported Q1 2026 revenue of $6.3M, down 16% YoY from $7.5M, and a GAAP net loss per share of -$0.06, in line with the prior year's -$0.07. Revenue missed the $8.5M consensus estimate by 26%. The company maintained its FY2026 guidance for double-digit revenue growth to surpass $40M and announced a definitive agreement to acquire Robocath. The revenue miss and ongoing transition from legacy J&J catheters overshadow the positive regulatory and acquisition news.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $6.3M declined 16% YoY from $7.5M, missing the $8.5M consensus estimate.
- GAAP net loss per share was -$0.06, compared to -$0.07 in Q1 2025; consensus was -$0.04.
- Recurring revenue fell to $5.0M from $5.5M YoY, pressured by the wind-down of the J&J catheter relationship.
- System revenue dropped to $1.3M from $2.0M YoY, reflecting only partial recognition on one Genesis system.
- Company maintained FY2026 guidance for double-digit revenue growth to surpass $40M, with Q3 and Q4 each expected to exceed $10M.
- Definitive agreement to acquire Robocath announced, combining complementary robotic technologies for endovascular procedures.
- Cash and cash equivalents stood at $14.6M with no debt; negative free cash flow was -$3.5M vs -$1.8M a year ago.
- MAGiC catheter received U.S. FDA approval in January; Synchrony digital OR system received FDA clearance in April.
Financial Impact
Revenue miss of $2.2M (26% below consensus) and net loss per share of -$0.06 vs consensus -$0.04.
Risk Factors
- Manufacturing ramp for MAGiC and GenesisX may fall short of the 500 catheters/month target by year-end.
- Integration of Robocath could divert management attention and increase cash burn.
- Dependence on winding down the J&J relationship creates a revenue gap that new products must fill.
- Cash balance of $14.6M may require additional financing before reaching profitability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022488 |
| Document: form8-k.htm | 0001493152-26-022488 |
| Document: 0001493152-26-022488-index-headers.html | 0001493152-26-022488 |
| Document: 0001493152-26-022488-index.html | 0001493152-26-022488 |
| Document: 0001493152-26-022488.txt | 0001493152-26-022488 |
| 8-K Data (Synthetic) | 0001493152-26-022488 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 7w ago | Press Release | $1.39 $1.18 | ▼ −15.11% | ▼ −13.92% | $1.03 (−25.90%) |
Aug 14, 2026 10w ago | EFFECT | $1.38 $1.33 | ▲ +3.62% | ▲ +1.63% | $1.03 (+25.36%) |
Aug 14, 2026 10w ago | EFFECT | $1.38 $1.33 | ▲ +3.62% | ▲ +1.63% | $1.03 (+25.36%) |
Aug 11, 2026 10w ago | Press Release | $1.40 $1.30 | ▼ −7.14% | ▼ −5.25% | $1.03 (−26.43%) |
Jul 15, 2026 14w ago | S-3 | $1.65 $1.38 | ▲ +16.36% | ▲ +19.98% | $1.03 (+37.58%) |
Jul 15, 2026 14w ago | S-3 | $1.65 $1.38 | ▼ −16.36% | ▼ −19.98% | $1.03 (−37.58%) |
Jul 9, 2026 15w ago | 8-K | $1.74 $1.36 | ▼ −21.84% | ▼ −24.08% | $1.03 (−40.80%) |
May 12, 2026 23w ago | 8-K | $1.85 $1.82 | ▲ +1.62% | ▲ +1.01% | $1.03 (+44.32%) |
May 12, 2026 23w ago | Press Release | $1.85 $1.82 | ▼ −1.62% | ▼ −1.01% | $1.03 (−44.32%) |
Apr 21, 2026 27w ago | Press Release | $1.92 $1.78 | ▼ −7.29% | ▼ −12.21% | $1.03 (−46.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers